of in vitro receptor autoradiography, this study aims at determining whether the higher level of kinin B 2 receptor density in the spinal cord of the spontaneously hypertensive rat (SHR) is secondary to arterial hypertension and whether chronic treatment with angiotensin I-converting enzyme inhibitors (ACEI) can regulate neuronal B 1 and B2 receptors. SHR received, from the age of 4 wk, one of the two ACEI (lisinopril or zofenopril, 10 mg ⅐ kg Ϫ1 ⅐ day Ϫ1 ) or for comparison, the selective AT1 antagonist (losartan, 20 mg ⅐ kg Ϫ1 ⅐ day Ϫ1 ) in their drinking water for a period of 4, 12, and 20 wk. Agematched untreated SHR and Wistar-Kyoto rats (WKY) were used as controls. B 2 receptor binding sites in most laminae were higher in SHR than in WKY from the age of 8 to 24 wk. Whereas B1 receptor binding sites were significantly present in young SHR and WKY, they were barely detectable in adult rats. ACEI (16 and 24 wk) and AT 1 antagonist (24 wk) enhanced the number of B 2 without changing B1 receptor binding sites. However, at 8 wk the three treatments significantly increased B1 and decreased B2 receptors in lamina I. It is concluded that 1) the higher density of B2 receptors in the spinal cord of SHR is not due to hypertension, 2) kinin receptors are regulated differently by ACEI in neuronal and vascular tissues, and 3) aging may have a profound impact on levels of B 1 and B2 receptors in the rat spinal cord. bradykinin; B1 receptor; B2 receptor; hypertension KININ-RELATED PEPTIDES referring mainly to bradykinin (BK) and kallidin (Lys-BK) were identified as neuromediators in the central control of arterial blood pressure and nociceptive information (7, 8) . Kinins act on two transmembrane G protein-coupled receptors denoted as B 1 and B 2 receptors (38, 39). The widely distributed B 2 receptor is constitutive and mediates most of the biological effects of kinins. Whereas the B 1 receptor is absent or underexpressed under physiological conditions, this receptor is induced and upregulated during tissue injury or in the presence of cytokines (27). The induction of B 1 receptor by cytokines involves the transcriptional nuclear factor B and the mitogen-activated protein kinase (35, 40, 46) .
noted as B 1 and B 2 receptors (38, 39) . The widely distributed B 2 receptor is constitutive and mediates most of the biological effects of kinins. Whereas the B 1 receptor is absent or underexpressed under physiological conditions, this receptor is induced and upregulated during tissue injury or in the presence of cytokines (27) . The induction of B 1 receptor by cytokines involves the transcriptional nuclear factor B and the mitogen-activated protein kinase (35, 40, 46) .
Kinins are metabolized by a group of carboxypeptidases named kininases I and II. Kininase I removes the COOH-terminal arginine from the parent molecules to yield the active metabolites des-Arg 9 -BK and des-Arg 10 -kallidine, which act as potent B 1 receptor agonists (39) . Kininase II, also known as angiotensin I-converting enzyme (ACE), is responsible for the inactivation of kinins and the generation of angiotensin II (14) . Breakdown inhibition of vasoactive kinins is believed to contribute to the therapeutic effects of ACE inhibitors (ACEI) in the treatment of hypertension and other cardiovascular diseases (21, 22) . A recent study also reported an upregulation of B 1 receptors at both mRNA and functional levels in vascular and renal tissues from normotensive rats and mice under chronic treatment with ramipril, an ACEI (29) .
Recent work suggests a putative role for central kinin receptors in arterial hypertension. For instance, the increased number and expression of B 2 receptors have been shown in the cardiovascular centers of the human medulla from hypertensive donors (12) and in the hypothalamus and cardiovascular medullary nuclei of spontaneously hypertensive rats (SHR) (8, 36) . Higher density of B 2 receptor binding sites in the thoracic spinal cord, an important center of autonomic control of blood pressure, was correlated with a greater cardiovascular response to intrathecal injection of BK in 16-wk-old SHR (6) . However, there is no evidence so far that the upregulation of B 2 receptors in the spinal cord and brain of SHR is causal or secondary to arterial hypertension.
Therefore, the aims of this study were to determine whether 1) the higher density of spinal B 2 receptors in SHR is secondary to arterial hypertension or is related to a genetic feature of the strain, and 2) ACEI can regulate the expression of B 1 receptors in the thoracic spinal cord of SHR as observed in peripheral vascular and renal tissues. These issues were addressed by measuring the effects of three antihypertensive agents, including two unrelated classes of ACEI [lisinopril without sulfhydryl (SH) group and zofenopril with SH group] and one antagonist of angiotensin AT 1 receptor (losartan), which is commonly used in the treatment of human hypertension (17) , on the density of B 1 and B 2 receptor binding sites in the thoracic spinal cord (T9-T10) of SHR by in vitro autoradiography. The effects of ACEI and losartan on kinin receptor densities were evaluated in young SHR at the onset of hypertension (8 wk old, after 4 wk of treatment) and in adult SHR during the established phase of hypertension (16 and 24 wk old, after 12 and 20 wk of treatment). Data were compared with age-matched untreated SHR and normotensive Wistar-Kyoto rats (WKY), which also allowed the determination of the effect of aging on the level of receptor binding sites. H Hyperfilm (single-coated, 24 ϫ 30 cm) were purchased from Amersham Pharmacia Biotech Canada. Losartan (Cozaar tablet), lisinopril, PIPES, 1,10-phenanthroline, dithiothreitol, bacitracin, captopril, and BSA (protease free) were purchased from SigmaAldrich Canada, and zofenopril was a gift from Menarini Ricerche Sireneze in Italy.
EXPERIMENTAL PROCEDURES

Chemicals and materials. HPP-desArg
Peptide iodination. Iodination of HPP-desArg 10 -HOE 140 and HPP-HOE 140 was performed according to the chloramine T method (19) . Briefly, 5 g of peptide were incubated in 0.05 M phosphate buffer for 30 s in the presence of 0.5 mCi (18.5 MBq) of 125 I-labeled Na and 220 nmol of chloramine T in a total volume of 85 l. The monoiodinated peptide was then immediately purified by high pressure liquid chromatography on a C4 Vydac column (0.4 ϫ 250 mm) (The Separations Group, Hesperia, CA) with 0.1% trifluoroacetic acid and acetonitrile as mobile phases. The specific activity of the iodinated peptides corresponds to 2,000 counts ⅐ min Ϫ1 ⅐ fmol Ϫ1 or 1,212 Ci/mmol. Animal source and care. Male SHR (n ϭ 48) and WKY (n ϭ 12) were purchased from Charles River (St-Constant, Qué-bec, Canada). They were individually housed in wire-bottom cages, in rooms under controlled temperature (23°C), humidity (50%), and lighting (12:12-h light-dark cycle) with food (Charles River Rodent) and tap water available ad libitum. All animal procedures were in strict compliance with the guiding principles for animal experimentation as enunciated by the Canadian Council on Animal Care and approved by the Animal Care Committee of our University.
Treatments of SHR. SHR received from the age of 4 wk, one of the two ACEI, lisinopril or zofenopril (10 mg ⅐ kg Ϫ1 ⅐ day Ϫ1 ), or the selective AT1 receptor antagonist, losartan (20 mg ⅐ kg Ϫ1 ⅐ day Ϫ1 ), in their drinking water for a period of 4, 12, and 20 wk. To ascertain that the animals took the expected dose of the drug, the daily water intake and body weight were taken into account and adjusted accordingly. Control age-matched SHR and WKY had no treatment during the same periods. Equiactive oral dose of zofenopril and lisinopril was selected, based on an earlier study using ex vivo inhibition of tissue ACE in SHR (9) . The dose of losartan selected was found to be effective in chronic studies in SHR (16, 42, 43) . Before euthanasia, mean arterial blood pressure (MAP) was measured in awake animals at the age of 8, 16, and 24 wk with a catheter implanted 24 h earlier into the abdominal aorta through the femoral artery and exteriorized at the back of the neck. The latter surgery was made under anesthesia with pentobarbital sodium (65 mg/kg ip). Body weight of animals was measured daily from the onset of treatments.
Tissue preparation for autoradiography. Rats were euthanized at the age of 8, 16, and 24 wk by asphyxia by respiratory CO 2 inhalation and subjected to dorsal laminectomy. Spinal cords (segments T8-T11) were immediately removed after careful incision of the dura mater and frozen in 2-methylbutane cooled at Ϫ45 to Ϫ55°C with liquid nitrogen and then stored at Ϫ80°C until use. Matched spinal cord segments (T9 to T10) of the four rats from the same experimental group were mounted together in a gelatin block and serially cut into 20-m-thick coronal sections with a cryostat fixed at temperatures varied between Ϫ11 and Ϫ13°C. Thus each section of the cryostat was from four spinal cords. A total of eight sections per slide were then alternatively thawmounted on 0.2% gelatin-0.033% chromium potassium sulfate-coated slides. Three slides were taken for the total binding and two slides (adjacent sections) for the nonspecific binding. A total of 50 slides (1,600 sections) were obtained for each group studied and kept at Ϫ80°C until use.
In vitro receptor autoradiography. Sections were thawed, preincubated for 30 s in 25 mM PIPES buffer (pH 7.4; 4°C), and incubated at room temperature for 90 min in the same buffer containing 1 mM 1,10-phenanthroline, 1 mM dithiothreitol, 0.014% bacitracin, 0.1 mM captopril, 0.2% BSA (protease free), and 7.5 mM magnesium chloride in the presence of 150 pM 125 I-labeled HPP-desArg 10 10 -HOE 140 for B1 receptor and HPP-HOE 140 for B2 receptor). To ascertain the specificity of the labeled B2 radioligand, the same concentration of unlabeled B1 ligand was added to the solution. Likewise, the same concentration of the unlabeled B2 ligand was added to the labeled B1 ligand solution. At the end of the incubation period, slides were transferred sequentially through four rinses of 4 min each in 25 mM PIPES (pH 7.4; 4°C), dipped for 15 s in distilled water (4°C) to remove the excess of salts, and then air-dried. 3 H Hyperfilm was juxtaposed onto the slides in the presence of 125 I microscales and exposed at room temperature for 3 days (B1 ligand) or 2 days (B2 ligand). The films were developed in D-19 (Kodak developer) and fixed in Kodak Ektaflo. Autoradiograms were quantified by densitometry using an image analysis system (MCID Imaging Research; Ontario, Canada). Standard curve from 125 I microscales was used to convert density levels into fentomoles per milligram of tissue. Specific binding was determined by subtracting superimposed digitalized images of nonspecific labeling from total binding. The anatomic structures with the corresponding nomenclature are depicted in Fig. 1 and adapted from the Atlas of Paxinos and Watson (33) .
Statistical analysis of data. Results represent the means Ϯ SE of four animals per group. Quantification was performed on 400 sections for each spinal cord (T9-T10) on both sides. Statistical analysis of data was performed with the GraphPad Prism computer program, and the statistical significance between SHR and WKY was determined with a Student's t-test for unpaired samples. For multiple comparisons to the same control group (untreated SHR), a one-way analysis of variance (ANOVA) followed by the test of Dunnett was employed. A one-way ANOVA in conjunction with Bonferroni confidence intervals was used for multiple comparisons between WKY and SHR. Only P values Ͻ0.05 were considered to be statistically significant.
RESULTS
Body weight and blood pressure. Body weight and baseline MAP in SHR and WKY are shown in Fig. 2 . At the onset of the treatment (4 wk) and at 24 wk, no statistical difference was found in body weight between SHR and WKY in all groups. However, the body weight of SHR at 8 and 16 wk was significantly higher than in age-matched WKY. Chronic treatment with zofenopril and lisinopril (16 wk) prevented excessive body weight gain in SHR. At 8 wk, the difference in body weight between strains was no more significant with lisinopril.
MAP was significantly augmented in SHR at 8, 16, and 24 wk compared with age-matched WKY. Whereas zofenopril and losartan prevented the development of hypertension from 8 to 24 wk in SHR, the reduction of MAP produced by lisinopril was greater and caused significant hypotension throughout the treatment. 10 -HOE 140 labeling was detected in the dorsal horn lamina I of which its density was significantly higher at 8 wk in SHR (2 fmol/mg tissue) than in age-matched WKY (1.14 fmol/mg tissue). The other structures of the spinal cord gray matter of 8-wkold SHR and WKY had lower specific densities of B 1 receptors (around 1.0 fmol/mg tissue) with no statistical difference between strains (Fig. 4) . The addition of 1 M of unlabeled HPP-desArg 10 -HOE 140 to the incubation medium completely eliminated the labeling in all laminae (Fig. 3) . However, a background of very low specific labeling to B 1 receptor was found in all laminae (values Յ0.5 fmol/mg tissue) in 16-and 24-wk-old WKY and SHR (data not shown). Densities of B 2 receptors were higher in the dorsal horn (lamina I Ͼ lamina II), and one-to eightfold greater in SHR. Also, values in lamina I were significantly higher at 16 wk than at 8 and 24 wk in SHR (P Ͻ 0.01), whereas values were lower at 8 wk (P Ͻ 0.01) and similar at 16 and 24 wk in WKY. The corresponding densities in lamina I were as follows: 3.35, 9.90, and 9.42 fmol/mg tissue for WKY and 20.14, 47.11 and 24.29 fmol/mg tissue for SHR at the age of 8, 16, and 24 wk, respectively. Although densities of specific binding sites were relatively low in most other laminae, most values were generally significantly higher in SHR than in age-matched WKY at 16 and 24 wk old ( Table 1) .
Effects of long-term treatment with antihypertensive drugs. Effects of chronic treatments with ACEI (zofenopril or lisinopril) and a selective AT 1 receptor antagonist (losartan) were assessed on the densities of both kinin receptors in the spinal cord of SHR. The density of B 1 receptors in lamina I was significantly increased after 4 wk of treatment with lisinopril (ϩ16%, P Ͻ 0.01), losartan (ϩ6%, P Ͻ 0.01), and zofenopril (ϩ36%, P Ͻ 0.01), yet no significant changes were measured in the other laminae. In contrast, the density of B 2 receptors was markedly decreased in lamina I by the three treatments (Ϫ57% to Ϫ65%, P Ͻ 0.01) (Figs. 5 and 6) . B 2 receptor binding values in other laminae (except lamina II) were too small to discriminate a real effect with the drugs, and therefore they were not considered for the remainder of the study.
Contrary to results obtained at 8 wk, a longer period of treatment (16-and 24-wk-old SHR) with either ACEI produced a marked increase of B 2 receptor binding sites in laminae I and II of the spinal cord (Fig. 6) . Whereas the reduction of B 2 receptor binding sites seen with losartan at 8 wk persisted at 16 wk in SHR, the latter treatment caused a significant increase of B 2 receptor binding sites in laminae I and II at 24 wk (Fig.  6) . The latter augmentation of B 2 receptor binding sites was similar to that occurring with ACEI. However, at 16 and 24 wk, ACEI and losartan had no significant effect on B 1 receptor binding sites, which remained barely detectable in the spinal cord of SHR (data not shown).
DISCUSSION
The main findings of this study are 1) the greater density of B 2 receptor binding sites in the thoracic spinal cord of SHR is unlikely secondary to arterial hypertension because it subsisted in SHR subjected to antihypertensive therapy with ACEI or losartan; 2) aging has an opposite effect on the level of B 1 (26, 45) . The significance of the higher level of B 1 receptor expression in young SHR (lamina I) and its decline in all laminae in adult is not understood at the present time, yet the present finding is congruent with an earlier study that concluded that B 1 receptors are not involved in spinal cardiovascular regulation in adult SHR and WKY (6) . Because B 1 receptors are detectable only in young SHR, it is unlikely that they are responsible for the maintenance of high blood pressure in adult SHR. (24) . Activation of these receptors on sensory and noradrenergic terminals led to nociceptive and antinociceptive responses, respectively, in the rat tail-flick test (7, 20) .
A small population of B 2 receptors is also present in deeper laminae, including the intermediomedial and intermediolateral cell columns, the location of cell bod- ies, and dendrites of preganglionic sympathetic fibers, which are involved in the autonomic control of blood pressure (8) . Thus our data suggest that B 2 receptors are extensively distributed throughout sensory and autonomic areas in the spinal cord of WKY and SHR, where they may be implicated in the modulation of nociceptive information and in the spinal control of blood pressure (8) .
Effect of ACEI and AT 1 receptor antagonist on spinal kinin receptors. Apart from their distinctive pharmacokinetic and pharmacodynamic features, the therapeutic benefits of ACEI in the treatment of hypertension are thought to be class effects (41) . Two major groups of ACEI have been documented: those containing a SH group as captopril and zofenopril and those without a SH group represented by lisinopril (4). Lisinopril and zofenopril can pass the blood-brain barrier to produce significant inhibition of brain ACE activity after oral administration in SHR (9, 37) . However, in our study, while zofenopril normalized blood pressure and lisinopril caused hypotension, both ACEI produced similar changes in the density of B 1 and B 2 receptors in the spinal cord of SHR, suggesting that these changes are not associated with or without the presence of SH group of ACEI. Pharmacodynamic differences between zofenopril and lisinopril may however explain their distinct antihypertensive profile. Lisinopril was also more effective than zofenopril in reducing the body weight of overweight SHR. Because losartan was less effective in reducing body weight increase in SHR, the antiobesity effect of ACEI cannot be entirely ascribed to inhibition of the hypertrophic feature of angiotensin II. Thus a role for endogenous kinins cannot be excluded in this additional beneficial effect of ACEI on body weight.
In addition, pretreatment for 4 wk with ACEI or losartan, which prevented the development of hypertension in SHR, caused a further increase of B 1 receptors in lamina I yet a decrease of B 2 receptors. Upregulation of B 2 receptors occurred only after a longer treatment with ACEI (16 and 24 wk) or losartan (24 wk). These changes of B 1 and B 2 receptor densities in SHR are unlikely attributable to the antihypertensive effect of the treatment, because the prevention of hypertension with losartan did not reproduce ACEI-induced B 2 receptor upregulation at 16 wk. Although both ACEI and losartan reduced the number of B 2 receptors in SHR after 4 wk of treatment (8 wk old), the levels of B 2 receptors were still significantly higher in the dorsal horn of SHR compared with age-matched WKY. This evidence suggests that the higher densities of B 2 receptor binding sites in most laminae in SHR are related to a genetic feature of the strain and not to hypertension.
Whereas it is uncertain whether the greater number of B 2 receptors found in the spinal cord of SHR, particularly between the age of 8 and 16 wk, contributes to the pathogenesis of hypertension, the higher density of B 2 receptor binding sites was ascribed as the likely mechanism to explain the hypersensitivity of the pressor response to BK injected in the spinal cord of awake SHR (6). Higher concentrations of kinins, kininogen, kallikrein, and kininase II (ACE) activity were also reported in the cerebrospinal fluid of adult SHR compared with their normotensive controls, suggesting a hyperactive kallikrein-kinin system in the brain and spinal cord of SHR (for a review, see Ref. 8) . Because the activation of B 2 receptors in the spinal cord leads to increases of blood pressure through the stimulation of the sympathoadrenal system and the peripheral release of catecholamines (23) , increased sensitivity to the pressor action of BK along with increased number of receptors and endogenous ligands may contribute to the higher sympathetic tone generally reported in different models of hypertension, including SHR (10, 11) . This hypothesis remains to be challenged with a prolonged infusion of the entire spinal cord with specific kinin receptor antagonists because acute blockade of B 1 and B 2 receptors at the T-9 spinal cord level in SHR was insufficient to alter baseline blood pressure (6) . It is also possible that kinins act chiefly as neuromodulators and not as primary mediators of spinal autonomic functions (8) .
Reciprocal regulation of B 1 and B 2 receptors during aging and antihypertensive therapy. Interestingly, the downregulation of B 1 receptors from 8 to 24 wk was accompanied by an upregulation of B 2 receptors, suggesting an age-dependent regulation of kinin receptors in WKY and SHR. Moreover, the upregulation of B 1 receptors induced by the two ACEI and losartan at 8 wk was accompanied by a downregulation of B 2 receptors, suggesting again that these receptors are regulated in an opposite way by ACEI and losartan in SHR. This is in keeping with the phenomenon described previously where complete desensitization of B 2 receptors in inflammatory models or its deletion in B 2 receptor gene knockout mice led to overexpression of B 1 receptors (5, 13, 29) .
Conflicting data have been reported regarding the regulation of kinin receptors by ACEI. An early pharmacological study has reported an upregulation of B 1 receptors in the rabbit vascular system both in vivo and in vitro following acute treatment (18 h) with ACEI (32). More recently, acute inhibition of ACE (48 h) failed to upregulate the B 1 receptor (mRNA expression and function) in vascular and nonvascular peripheral organs of rabbits (28) . However, a 6-wk treatment with ramipril is associated with functional induction of vascular and renal B 1 receptor in normotensive rats, wild-type and B 2 receptor gene knockout mice (29) . Our results at 8 wk support an upregulation of B 1 receptors after 4 wk of treatment with ACEI, although a longer period of treatment (12 and 20 wk) had no effect. It is therefore apparent that this phenomenon occurs within a specific time window, and different conclusions can be drawn depending on the duration of the treatment. It is also noteworthy that contrary to B 1 receptors, vascular and renal B 2 receptor mRNA was not affected by ACEI in rats (29) , suggesting that kinin receptor expression is regulated differently in peripheral and central nervous tissues.
Possible mechanisms underlying the effects of ACEI and losartan on kinin receptors. The mechanism of downregulation and upregulation of neuronal B 2 receptors and upregulation of B 1 receptors by ACEI is still unknown. We can exclude that the radioligand binds to ACE or to other proteins as captopril was present throughout the autoradiographic procedure in all experimental groups and B 2 receptor binding sites seen with the same radioligand in the spinal cord of wild-type mice were gone in B 2 receptor gene knockout mice (8) .
Although ACEI do not act directly on B 2 receptors (14), they can interfere with the sequestration and internalization of B 2 receptors within the cellular membrane in native porcine aortic endothelial cells (3) and in Chinese hamster ovary cells (30) . An interaction with the process of B 2 receptor dimerization, which is directly involved in the endogenous and recycling of receptors, may represent another putative mechanism by which ACEI could affect B 2 receptor binding (2) . Also, the formation of stable heterodimers between B 2 and AT 1 receptors, which change the endocytotic pathway of both receptors and enhance G protein activation (1), may provide a possible mechanism by which losartan can affect the expression of B 2 receptors in our paradigm. On the other hand, the B 1 receptor is not subjected to internalization and resensitization; therefore, its regulation is more likely to occur at the transcriptional and mRNA levels (15, 46) . Because B 2 and B 1 receptors are largely synthesized outside the spinal cord in dorsal root ganglia (24, 34, 45) , one cannot exclude the possibility that the site of regulation of kinin receptors by ACEI and losartan is at the level of the cell body of primary sensory fibers.
